Search

A recent report published by researchers from Bukhara State Medical Institute discusses hepatorenal syndrome, a condition where kidney failure occurs due to liver cirrhosis. The report highlights that there are two types of hepatorenal syndrome, with type 1 being more severe and potentially leading to death if not treated within 2 weeks. Type 2 hepatorenal syndrome progresses more slowly but can still be fatal if left untreated for 4-6 months. The research emphasizes that type 2 hepatorenal syndrome is not often discussed in medical papers and involves a small number of people. [Extracted from the article]

A recent study conducted at Southwest Medical University in Sichuan, People's Republic of China, focused on the role of macrophages in liver fibrosis. The research analyzed publications from 2007 to 2023 and identified China as the leading country in this field. The study highlighted the importance of understanding the mechanisms by which macrophages influence liver fibrosis and suggested that macrophage-based therapies could be crucial in the future. This research provides valuable insights for future basic research and clinical practice in the treatment of liver fibrosis. [Extracted from the article]

Keywords: Bioengineering; Biotechnology; Cirrhosis; Drugs and Therapies; Fibrosis; Gastroenterology; Gene Therapy; Genetics; Health and Medicine; Liver Cirrhosis; Liver Diseases and Conditions; Liver Fibrosis EN Bioengineering Biotechnology Cirrhosis Drugs and Therapies Fibrosis Gastroenterology Gene Therapy Genetics Health and Medicine Liver Cirrhosis Liver Diseases and Conditions Liver Fibrosis 2189 2189 1 03/23/23 20230317 NES 230317 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on gene therapy. To summarize, this review paper sheds light on the most recent breakthroughs in drug and gene-based nano and targeted delivery systems that have lately shown useful for the treatment of liver fibrosis and cirrhosis.". [Extracted from the article]

Researchers at Guangxi University of Chinese Medicine have reported new data on liver fibrosis, focusing on the role of glucose metabolic pathways in regulating this condition. Liver fibrosis is a common feature of chronic liver diseases, and understanding the mechanisms behind it is crucial for developing effective treatments. The study highlights the potential of Chinese medicine, such as turmeric and rhubarb extracts, in targeting the metabolic reprogramming of hepatic stellate cells to combat liver fibrosis. This research provides valuable insights into the modernization of Chinese medicine and its potential in treating liver diseases. [Extracted from the article]

A patent application by inventors from Japan focuses on a composition for treating liver dysfunction using skeletal myoblasts. The method aims to promote liver cell proliferation, tissue regeneration, and angiogenesis through cytokine production. This approach could potentially address conditions such as hepatitis, liver fibrosis, cirrhosis, and liver cancer, offering new possibilities for treating liver dysfunction. [Extracted from the article]

Researchers at the College of Science have conducted a study on liver fibrosis using a unique interval-based approach with subintervals. The research explores the use of classical and fractal-fractional-order derivatives in each subinterval to study the existence of solutions and stability. The results were simulated using the extended Adams-Bashforth-Moulton method, providing numerical solutions for different fractal-fractional-order values. This study offers a new perspective on liver disease and mathematical modeling, contributing to the field of gastroenterology and health sciences. [Extracted from the article]

Researchers at the Chinese Academy of Medical Sciences have conducted a study on liver fibrosis, a condition that plays a crucial role in liver disease progression. The study focused on the synthesis and anti-liver fibrosis research of aspartic acid derivatives, with promising results showing inhibitory effects on liver fibrosis activity. The research identified new compounds with potent anti-liver fibrosis effects, paving the way for the development of novel treatments. For more information, the full article can be accessed through the publisher, MDPI AG. [Extracted from the article]

A research study conducted by Beijing University of Chinese Medicine explores the potential of Chinese medicine in treating liver fibrosis. Liver fibrosis is a common complication of chronic liver disease and can lead to cirrhosis and hepatocellular carcinoma. The study focuses on the regulation of signaling pathways related to liver fibrosis and how Chinese medicine can effectively treat the condition by interfering with these pathways. The research provides valuable insights for further study and clinical practice in the treatment of liver fibrosis. [Extracted from the article]

A study led by researchers at the University of Barcelona has identified a potential new strategy to slow the development of liver fibrosis, a serious complication of metabolic fatty liver disease. The study found that activation of the PPARb/d-AMPK pathway can effectively slow the progression of liver fibrosis. Liver fibrosis is the most relevant risk factor for predicting liver disease-related mortality and overall mortality. The findings suggest that activating the PPARb/d-AMPK pathway could be an effective strategy to reduce the development of liver fibrosis. [Extracted from the article]

A recent study conducted by researchers at the Affiliated Hospital of Southwest Jiaotong University aimed to analyze the research status and development trends in the pathogenesis of hepatic encephalopathy, a common complication of decompensated cirrhosis. The study used bibliometrics and knowledge mapping to analyze publications from 1978 to 2022. The results showed an increasing trend in annual publications, with the United States, the University of London, and Jasmohan S Bajaj being the most influential country, institution, and author, respectively. The study identified ammonia metabolism, gut microbiota, sarcopenia, and trace elements as future research frontiers in hepatic encephalopathy. [Extracted from the article]

Researchers from the First Affiliated Hospital of Gannan Medical University in China have conducted a systematic review and meta-analysis on the use of mesenchymal stem cell exosomes (MSC-exos) for the treatment of liver fibrosis. The study found that MSC-exos significantly improved liver function, promoted the repair of damaged liver tissue, and slowed the progression of hepatic fibrosis. Additionally, the combination of MSC-exos with drug therapy was found to be more effective than MSC-exos alone. However, further experimental validations are needed before these findings can be applied in clinical treatment. [Extracted from the article]

A study conducted by researchers at Manipal Academy of Higher Education in India has developed a new model called LivMarX, which uses biomarkers instead of images to accurately classify stages of liver cirrhosis. The model utilizes advanced machine learning algorithms and feature engineering techniques to analyze a comprehensive dataset of 424 patients. The study found that LivMarX outperformed other models with an accuracy of 84.33% and demonstrated a reliable staging of liver cirrhosis with an AUC of 0.95. This cost-effective and comfortable approach to diagnosis could be particularly beneficial in areas with limited access to complex imaging equipment. [Extracted from the article]

A new study conducted at Sri Ramakrishna Engineering College in Tamil Nadu, India, explores the use of automated computer-aided approaches to accurately predict the status of liver cirrhosis. The study focuses on the extraction of features from normal and cirrhotic liver ultrasonic images using clustering techniques like fuzzy c-means, possibilistic fuzzy c-means, and possibilistic c-means. These features are then classified as normal or cirrhotic using various classifiers, such as Gaussian mixture model, Softmax discriminant classifier, and SVM. The hybrid classifier AAO-GMM, with the PFCM feature, demonstrated the best performance, achieving an accuracy of 99.03% and an MCC of 0.90. This research provides valuable insights into liver cirrhosis detection from ultrasonic images. [Extracted from the article]

A study conducted by researchers at Guangxi University in China has proposed a new model for staging liver fibrosis based on image processing technology. The model, called EVO-MS, utilizes an ensemble learning approach and the energy valley optimization algorithm to select informative features for fibrosis quantification. The researchers found that selecting 3-5 feature parameters yielded satisfactory results in classification, with certain features significantly influencing accuracy. The EVO-MS model achieved an accuracy of 0.864, demonstrating its effectiveness in staging the degree of liver fibrosis. [Extracted from the article]

A recent study conducted by Hangzhou Medical College in China has explored the role of gut microbiota in liver cirrhosis. The study used bibliometric methods to analyze publications on this topic from 2001 to 2023. The analysis included 3109 articles from 96 countries, with notable contributions from the United States and China. The study identified key research institutions, prolific authors, and popular journals in this field. The findings provide valuable insights into the current research frontiers and hotspots, serving as a guide for scholars interested in gut microbiota and liver cirrhosis. [Extracted from the article]

A recent report from investigators at Shanghai University of Traditional Chinese Medicine highlights the effectiveness of compound formulas of traditional Chinese medicine (TCM) in the treatment of chronic liver diseases. The study reviews the composition, curative effects, and mechanisms of these formulas, focusing on chronic viral hepatitis, nonalcoholic fatty liver disease, cholestatic liver disease, and liver fibrosis or cirrhosis. The research concludes that the benefits of TCM compound formulas in treating chronic liver diseases are constantly evolving due to advancements in medical technology. This study provides valuable insights for individuals interested in exploring the integration of TCM and Western medicine for the treatment of liver diseases. [Extracted from the article]

New research from Jagiellonian University Medical College in Krakow, Poland, explores the potential of ultrasound elastography as an alternative method to liver biopsy for assessing liver fibrosis in pediatric patients. Liver diseases are increasingly common in children, and the current gold standard for diagnosis is liver biopsy, which is invasive and requires general anesthesia. The study concludes that while ultrasound elastography cannot currently replace liver biopsy, its role in monitoring pediatric patients with liver diseases is expected to grow in the future. This research has been peer-reviewed and published in Advances in Medical Sciences. [Extracted from the article]

A recent study conducted at General Hospital de Tomelloso in Spain has found that non-alcoholic fatty liver disease (NAFLD) is a common condition in patients with inflammatory bowel disease (IBD). The study analyzed 89 studies and found that the overall prevalence of NAFLD in IBD patients was 24.4%. The prevalence of NAFLD has increased in recent years and is higher in male patients compared to female patients. The study also found that the prevalence of liver fibrosis in IBD patients was 16.7%. The researchers concluded that one-quarter of IBD patients worldwide may have NAFLD, with higher rates in recent studies and those that used current diagnostic methods. [Extracted from the article]

Keywords: Chengdu; People's Republic of China; Asia; Biological Factors; CD Antigens; Chemokine Receptors; Chemokines; Chemotactic Factors; Cytokine Receptors; Cytokines; G-Protein-Coupled Receptors; Gastroenterology; Health and Medicine; Immunology; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Liver Cirrhosis; Liver Diseases and Conditions; Liver Fibrosis; Membrane Proteins EN Chengdu People's Republic of China Asia Biological Factors CD Antigens Chemokine Receptors Chemokines Chemotactic Factors Cytokine Receptors Cytokines G-Protein-Coupled Receptors Gastroenterology Health and Medicine Immunology Inflammation Mediators Intercellular Signaling Peptides and Proteins Liver Cirrhosis Liver Diseases and Conditions Liver Fibrosis Membrane Proteins 789 789 1 08/28/23 20230901 NES 230901 2023 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Current study results on Liver Diseases and Conditions - Liver Fibrosis have been published. The roles of chemokines including the CC, CXC and CX3C families on liver inflammation and fibrosis were described by the Wasmuth HE team ten years ago. [Extracted from the article]

Digestive System Diseases and Conditions, Gastroenterology, Health and Medicine, Hepatology, Liver Cirrhosis, Liver Diseases and Conditions Keywords: Digestive System Diseases and Conditions; Gastroenterology; Health and Medicine; Hepatology; Liver Cirrhosis; Liver Diseases and Conditions EN Digestive System Diseases and Conditions Gastroenterology Health and Medicine Hepatology Liver Cirrhosis Liver Diseases and Conditions 86 86 1 07/03/23 20230703 NES 230703 2023 JUL 3 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Investigators publish new report on liver cirrhosis. [Extracted from the article]

Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B. EXCLUSION CRITERIA: Patients undergoing emergency surgery; inability to understand informed consent. Keywords: Cancer; Carcinomas; Cardiovascular Diseases and Conditions; Clinical Research; Clinical Trials and Studies; Digestive System Diseases and Conditions; Gastroenterology; Health and Medicine; Hemic and Immune Systems; Hepatic Failure; Hepatology; Hypertension; Liver Cancer; Liver Cirrhosis; Liver Diseases and Conditions; Liver Diseases and Conditions - Portal Hypertension; Lymphoid Tissue; Oncology; Portal Hypertension; Risk and Prevention; Spleen; Surgery EN Cancer Carcinomas Cardiovascular Diseases and Conditions Clinical Research Clinical Trials and Studies Digestive System Diseases and Conditions Gastroenterology Health and Medicine Hemic and Immune Systems Hepatic Failure Hepatology Hypertension Liver Cancer Liver Cirrhosis Liver Diseases and Conditions Liver Diseases and Conditions - Portal Hypertension Lymphoid Tissue Oncology Portal Hypertension Risk and Prevention Spleen Surgery 636 636 1 04/17/23 20230418 NES 230418 2023 APR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Staff editors report on the newly launched clinical trial, NCT05800561, which has the following summary description: "AIMS To evaluate the accuracy of HVPG (direct method), ICG-R15 and LSM/SSM (non-invasive methods) in predicting the risk of PHLF and hepatic decompensation; to evaluate the correlation between hepatic functional reserve (ICG-R15) and degree of portal hypertension (HVPG) and LSM/SSM in Child Pugh 0, A and B cirrhotic patients; to evaluate the real weight of HVPG in a multivariate analysis. [Extracted from the article]

Keywords: Gastroenterology; Health and Medicine; Liver Cirrhosis; Liver Diseases and Conditions; Liver Fibrosis EN Gastroenterology Health and Medicine Liver Cirrhosis Liver Diseases and Conditions Liver Fibrosis 696 696 1 04/10/23 20230413 NES 230413 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- New research on liver fibrosis is the subject of a new report. Gastroenterology, Health and Medicine, Liver Cirrhosis, Liver Diseases and Conditions, Liver Fibrosis. [Extracted from the article]

Biomarkers, Cancer, Carcinomas, Diagnostics and Screening, Digestive System Diseases and Conditions, Gastroenterology, Health and Medicine, Hepatology, Liver Cancer, Liver Cirrhosis, Liver Diseases and Conditions, Oncology Keywords: Biomarkers; Cancer; Carcinomas; Diagnostics and Screening; Digestive System Diseases and Conditions; Gastroenterology; Health and Medicine; Hepatology; Liver Cancer; Liver Cirrhosis; Liver Diseases and Conditions; Oncology EN Biomarkers Cancer Carcinomas Diagnostics and Screening Digestive System Diseases and Conditions Gastroenterology Health and Medicine Hepatology Liver Cancer Liver Cirrhosis Liver Diseases and Conditions Oncology 767 767 1 04/10/23 20230411 NES 230411 2023 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in liver cirrhosis. [Extracted from the article]

2024 MAY 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on pharmacology. According to news reporting out of [...]

Byline: Moneylife Digital Team While upholding an order passed by the state commission, the national consumer disputes redressal commission (NCDRC) noted that there is suppression of material facts by the [...]

Byline: Ullekh NP Non-alcoholic liver diseases in teens and hardworking villagers portend a crisis for India SONAM SHENOY, a techie-turned-homemaker based in Lower Parel, Mumbai, had always frowned upon her [...]

2020 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

2019 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Autoimmune Diseases and Conditions - Autoimmune Hepatitis is [...]

2018 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers detail new data in Liver Diseases and Conditions. According to news [...]

2017 AUG 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- CAMBRIDGE, Mass. -- Many diseases, including cirrhosis and hepatitis, can lead to [...]

2017 JUL 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Researchers have identified the mechanism which causes a build-up of fat in [...]

2016 APR 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Nonalcoholic fatty liver disease, or NAFLD, comprises a group of liver disorders [...]

Another Argument for Moderation in All Things Abstract & Commentary By Barbara A. Phillips, MD, MSPH, Professor of Medicine, University of Kentucky; Director, Sleep Disorders Center, Samaritan Hospital, Lexington. Dr. [...]

The liver is very soft when it's healthy; fibrosis firms the tissue. Cirrhosis makes it rock hard. Half of those patients who progress to this stage are dead within five [...]